Unaudited Financial Results of the Company for the quarter ended 30th September, 2025 along with the Limited Review Report issued by the Statutory Auditors of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ishita Drugs & Industries reported unaudited results for the quarter and half year ended 30 September 2025, approved at the board meeting on 11 November 2025. The statutory auditor issued a clean (unqualified) Limited Review Report with no qualifications or observations. Profit before tax for H1 FY26 stood at Rs. 60.89 lakhs versus Rs. 115.51 lakhs for full FY25. Operating cash flow turned strongly positive at Rs. 412.24 lakhs versus a negative Rs. 363.71 lakhs last year, supported by a sharp reduction in inventories (Rs. 446.49L to Rs. 164.60L) and trade receivables (Rs. 189.82L to Rs. 61.08L). Current borrowings also fell sharply from Rs. 381.35L to Rs. 193.23L, strengthening the balance sheet. Total assets stood at Rs. 1,457.37 lakhs against equity of Rs. 1,123.53 lakhs. The MD also informed that the manufacturing facility upgradation for Revised Schedule M compliance has commenced, with Rs. 50 lakhs already spent on civil construction, though work has been delayed due to above-normal rainfall and an extended monsoon.
Clean audit report, strong positive operating cash flow, and meaningful debt reduction are positives for shareholders. However, the capex project delay from monsoon disruption is a minor watchpoint; near-term profitability remains modest given the small scale of operations.